AccelStor Announces New Flagship All-Flash Array: The NeoSapphire P710
AccelStor, the software-defined all-flash array provider, is thrilled to announce the next generation NeoSapphire P710, its latest flagship all-flash array. The P710 pushes performance to a new level: over 700K IOPS for 4KB random writes. It adds abundant software features including snapshot, snapshot backup, Free Clone, thin provisioning, thick provisioning, inline deduplication (Zero Page) and vSphere Web Client Plug-in, with zero performance trade-offs. All these make the P710 perfect for VDI environments and the first choice for users that need high performance combined with versatile software functions and data protection features. With a wealth of software advantages, the NeoSapphire P710 is apt for any demanding applications.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161207005019/en/
AccelStor New Flagship All-Flash Array: NeoSapphire P710 (Photo: Business Wire)
“The big data and VDI revolution are driving new requirements for our customers, and pushes the limits of our design team,” said Dr. Charles Tsai, President of AccelStor, “By broadening our software functionality, including new tools for VDI environments, we’re determined to be the go-to solution for any I/O intensive storage applications.”
A New Level of Storage Performance
Supported by FlexiRemap Technology, the NeoSapphire P710 all-flash array boasts the highest IOPS of the series – over 700K IOPS for 4KB random write, an over 16% increase from its predecessor, the NeoSapphire 3413. The P710 comes with 11TB or 23TB usable capacity and adopts the same rack-mount 2U form factor, storing up to 24 hot-swappable enterprise SSDs including 2 global hot spares. This new generation of all-flash arrays supports both 10GbE and 16G Fibre Channel connectivity for blazing-fast throughput.
Snapshots for Software-Level Protection
With the P710, NeoSapphire users can now quickly and seamlessly recover their data to particular instances through its snapshot function. The scheduled snapshot and the associated restore feature can have data backed up by remote storage for extra security. By quickly reverting to previous storage states, users can be assured that their data is protected, even on top of the high level of existing redundancy.
Brand New Tools for VDI Applications
AccelStor’s special Free Clone function allows users to cut down on time-consuming volume cloning for VDI applications without allocating a physical capacity. AccelStor’s new vSphere Web Client Plug-in provides easy management for VMware administrators who can create, delete, and clone datastores in the integrated GUI, without needing to access the main web UI. Users can choose to enable thin provisioning or thick provisioning for greater flexibility when creating virtual disks. P710 is also certified for VAAI Block as VMware Ready Storage
Rock-Solid Reliability and Redundancy
All 24 SSDs in the NeoSapphire P710 are hot-swappable; 2 of these SSDs are hot spares for redundancy. In tandem with the new snapshot backup feature, this level of fault tolerance ensures that data is protected and always recoverable.
The 10GbE SKU of the NeoSapphire P710 is presently ready with available samples for customer evaluation. The Fibre Channel SKU will be available in January 2017. For product details and specifications, visit the NeoSapphire P710 product page: https://www.accelstor.com/overview.php?id=19
AccelStor is accelerating the paradigm shift from conventional disk arrays to modern all-flash storage. AccelStor's NeoSapphire series all-flash arrays, powered by FlexiRemap software technology, deliver sustained high IOPS to business-critical applications. With standard rack-mount form factors, streamlined storage management, multi-protocol support, as well as front-accessible and hot-swappable drives, NeoSapphire promises to resolve the performance bottlenecks for I/O-intensive applications like virtualization, high-performance computing, database, and media-processing applications. For more information about AccelStor and NeoSapphire, please visit www.accelstor.com.
* AccelStor, FlexiRemap, and NeoSapphire are trademarks or registered trademarks of AccelStor, Inc. in the United States of America and/or other countries.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i